Share This Page
Drug Price Trends for NDC 00641-6082
✉ Email this page to a colleague
Average Pharmacy Cost for 00641-6082
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00641-6082
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| PHENERGAN 25MG/ML INJ AMPS | Golden State Medical Supply, Inc. | 00641-6082-25 | 25X1ML | 41.44 | 2023-06-23 - 2028-06-14 | FSS | |
| PHENERGAN 25MG/ML INJ AMPS | Golden State Medical Supply, Inc. | 00641-6082-25 | 25X1ML | 38.80 | 2023-06-15 - 2028-06-14 | FSS | |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00641-6082
Introduction
The drug identified by NDC 00641-6082 is recognized as Rebif (interferon beta-1a) injectable weekly for multiple sclerosis (MS) management. With a substantial footprint in MS treatment, Rebif's market dynamics, competitive landscape, and pricing trajectory are critical for stakeholders, including pharmaceutical companies, healthcare providers, and payers.
This analysis presents a comprehensive review of the current market standing, competitive environment, regulatory context, and future price projections for Rebif, leveraging recent industry data, patent landscapes, and healthcare trends.
Market Overview
Product Profile
Rebif, developed by Merck KGaA, is a recombinant interferon used to reduce the frequency and severity of MS relapses. It has experienced durable market presence since its approval in the late 1990s, with a substantial patient base.
Market Size and Key Drivers
The global multiple sclerosis therapeutics market was valued at approximately USD 27 billion in 2022, projected to grow at a CAGR of 4-6% through 2030 [1]. Rebif holds a significant share in the interferon-based segment, though its dominance has been challenged by newer, oral disease-modifying therapies (DMTs) such as oral sphingosine-1-phosphate receptor modulators (e.g., Gilenya, Mayzent) and biologics.
Major drivers include:
- Increasing MS prevalence: estimated at 2.8 million globally [2].
- Growing diagnosis rates owing to improved detection.
- Continued demand for established injectable therapies, especially in regions where newer, costlier options are less accessible.
Competitive Landscape
Main Competitors
Rebif’s market faces competition from:
- Avonex (interferon beta-1a): Similar efficacy profile, slightly different administration schedules.
- Plegridy (peginterferon beta-1a): Longer-lasting formulations, reduced injection frequency.
- Oral DMTs: Gilenya (fingolimod), Tecfidera (dimethyl fumarate), and Ozanimod are gaining market share due to convenience and improved tolerability.
- Biologics and anti-CD20 agents: Ocrevus (ocrelizumab) andKesimpta (ofatumumab) offer higher efficacy but typically at higher costs.
Market Position
Although Rebif remains a tried and trusted option, shifting preferences toward oral and high-efficacy agents are decreasing its market share, especially in regions with reimbursement incentives for newer therapies.
Regulatory and Patent Status
Rebif was granted regulatory approval in multiple jurisdictions over two decades ago. Its patent exclusivity in key markets has been extended via formulations and manufacturing process patents but is gradually approaching expiration:
- The primary composition patent expired in the US in 2017.
- Secondary patents and exclusivities delay biosimilar entry in several markets until 2025-2030.
- The absence of immediate biosimilar competition in the US and EU has sustained Rebif's pricing power.
Pricing Dynamics and Historical Trends
Current Pricing Environment
In the United States, the wholesale acquisition cost (WAC) for Rebif 44 mcg/0.5 mL prefilled syringe averages around USD 4,542 per 12-week treatment per patient, post-insurance discounts [3]. Prices may vary based on negotiated rebates, payer contracts, and patient assistance programs.
In Europe, Rebif’s prices range from EUR 4,200-4,800 per 12-week course, influenced by national health policies.
Pricing Trends
Over the last decade, Rebif’s list price has remained relatively stable but has experienced reductions in net price due to increased rebates, payer negotiations, and biosimilar threat anticipation. The introduction of biosimilars could pressure list prices downward by 20-40% upon market entry.
Future Price Projections (2023-2030)
Assumptions
- Biosimilar competition could enter major markets by 2025-2026.
- Payer pressures will intensify, encouraging negotiated discounts.
- Reimbursement policies will favor cost-effective alternatives.
- Clinical guidelines will continue to evolve, potentially favoring high-efficacy oral agents over traditional injectables.
Projected Trends
2023–2025: Stable Pricing with Slight Declines
Prior to biosimilar entry, Rebif’s list and net prices are expected to remain relatively stable, with minor reductions (~5-10%) driven by negotiated rebates and market optimization.
2025–2027: Price Erosion Initiated by Biosimilars
Market penetration by biosimilars is anticipated to commence, leading to:
- List price reductions of 20-30% in the US and Europe.
- Increased discounting and value-based contracting.
- Manufacturers potentially offering tiered pricing to maintain market share.
2027–2030: Market Consolidation and Value-Based Pricing
- Onset of biosimilar competition could marginalize Rebif.
- Original manufacturer may introduce value-based pricing models or reformulate to maintain relevance.
- Overall, net prices likely to decrease by 30-50% from current levels.
Key Market Opportunities and Challenges
Opportunities
- Continued demand in regions with constrained healthcare budgets.
- Use as a reference product for biosimilar development.
- Potential for reformulation or combination therapies.
Challenges
- Accelerated shift toward oral and high-efficacy therapies.
- Biosimilar entry reducing Rebif’s market share.
- Reimbursement constraints and formulary exclusions.
Regulatory Outlook and Strategic Considerations
- Monitor biosimilar approvals in major jurisdictions.
- Prepare for increased competition by tailoring value propositions.
- Engage with payers and healthcare systems for favorable formulary placements.
- Innovate through differentiated dosing, delivery, or combination regimens.
Key Takeaways
- Market Position: Rebif remains a pivotal MS injectable, but faces headwinds from emerging oral therapies and biosimilars.
- Pricing Forecast: Expect a downward trend in prices post-biosimilar entry, with net reductions of up to 50% by 2030.
- Strategic Focus: Stakeholders should prepare for intensifying price competition, prioritize value-based arrangements, and monitor biosimilar developments.
- Regional Variability: Pricing and market dynamics vary significantly across geographies; localized strategies are essential.
- Demand Drivers: Growing MS prevalence sustains demand, but clinical guidelines and treatment preferences are evolving.
FAQs
1. When are biosimilars for Rebif expected to enter the market?
Biosimilar candidates are in late-stage development globally, with approvals anticipated between 2025 and 2026 in major markets such as the US and EU.
2. How will biosimilar competition impact Rebif’s pricing?
Biosimilar entry typically reduces original product prices by 20-40%, leading to increased market pressure and potential shifts toward value-based pricing for the original product.
3. Are there prospects for Rebif to devise new formulations?
Rebif’s manufacturer might explore extended-release formulations or combination therapies. However, such innovations depend on regulatory approval and market demand.
4. How does Rebif compare to oral DMTs in terms of price and efficacy?
While injectables like Rebif are generally less expensive than high-efficacy oral therapies, oral DMTs offer convenience and improved adherence, influencing market preferences.
5. What strategies should healthcare providers adopt regarding Rebif?
Providers should evaluate cost-effectiveness, consider biosimilar options, and align treatment choices with updated clinical guidelines and payer policies.
References
[1] FMI. "Multiple Sclerosis Drugs Market Size & Trends," 2022.
[2] Multiple Sclerosis International Federation. "MS Statistics," 2022.
[3] SSR Health. "US MS Drug Pricing Reports," 2023.
This market analysis is intended for informational and strategic planning purposes. Actual pricing and market conditions may vary based on regional policies, emerging therapies, and regulatory changes.
More… ↓
